Related Experiment Videos
Arterial distensibility and left ventricular hypertrophy in patients with sustained essential hypertension
Insights
Aortic stiffness contributes to cardiac hypertrophy in hypertension. Certain antihypertensive drugs improve arterial stiffness, aiding in the potential reversal of cardiac hypertrophy.
Area of Science:
- Cardiovascular Medicine
- Hypertension Research
- Vascular Physiology
Background:
- Reduced aortic distensibility and compliance are implicated in cardiac hypertrophy development in hypertensive patients.
- Increased end-systolic stress, influenced by ventricular geometry and systolic pressure, contributes to cardiac hypertrophy.
- Aortic rigidity, assessed via characteristic impedance or pulse-wave velocity, correlates with cardiac hypertrophy in sustained essential hypertension.
Purpose of the Study:
- To investigate the relationship between aortic stiffness and cardiac hypertrophy in hypertension.
- To evaluate the impact of different antihypertensive treatments on arterial stiffness and its potential role in cardiac hypertrophy reversal.
Main Methods:
- Assessment of aortic rigidity using characteristic impedance, carotid-femoral pulse-wave velocity, and Peterson elastic modulus.
- Analysis of the correlation between aortic stiffness parameters and the degree of cardiac hypertrophy.
- Comparison of the effects of dihydralazine-like substances, calcium-entry blockers, and converting-enzyme inhibitors on arterial stiffness.
Main Results:
- Aortic rigidity significantly correlates with the degree of cardiac hypertrophy in patients with sustained essential hypertension.
- Dihydralazine-like substances did not alter arterial stiffness.
- Calcium-entry blockers and converting-enzyme inhibitors improved arterial stiffness at equivalent blood pressure reduction levels.
Conclusions:
- Modifications in aortic and large artery stiffness are crucial factors in understanding the reversal of cardiac hypertrophy during antihypertensive therapy.
- Arterial stiffness is a significant determinant of cardiac hypertrophy in hypertensive individuals.
- Targeting arterial stiffness with specific antihypertensive agents may be key for managing cardiac hypertrophy.
Abstract:
Reduced aortic distensibility and compliance may participate in the genesis of cardiac hypertrophy in patients with hypertension. In these patients the increase in end-systolic stress, a determinant factor contributing to the development of cardiac hypertrophy, is influenced not only by the geometric properties of the ventricle but also by the level of systolic pressure. In patients with sustained essential hypertension, the degree of cardiac hypertrophy correlates significantly with the increase in aortic rigidity, which is assessed by the calculation of the characteristic impedance, by the measurement of carotid-femoral pulse-wave velocity, or by the calculation of the Peterson elastic modulus at the level of the aortic arch. Dihydralazine-like substances are unable to modify arterial stiffness, whereas calcium-entry blockers and converting-enzyme inhibitors improve arterial stiffness when achieving the same degree of blood pressure reduction. Modifications in the stiffness of the aorta and other large arteries must be considered to understand reversion of cardiac hypertrophy as a result of antihypertensive treatment.